GLP-1 agonists cut stroke, kidney mortality risk: review
The cardiovascular benefits of the diabetes drugs appear independent of glucose control, researchers say
The cardioprotective effects of GLP-1 receptor agonists in patients with type 2 diabetes — including novel findings for reduced stroke — are consistent across the drug class, a major review has shown.
Results from the largest pooled study on the agents to date also suggest the cardiovascular benefits are not confined to the human-based incretin mimetics but also extend to the older exendin-4-based drugs, the UK-led researchers say.
And the findings bolster the growing body of evidence
